BBC

Virtus LifeSci Biotech Clinical Trials ETF [BBC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BBC Stock Summary

Top 10 Correlated ETFs

BBC

Top 10 Correlated Stocks

BBC

In the News

BBC Financial details

Company Rating
-
Market Cap
11.64M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.08
Dividend %
0.31%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
0.23%
SMA50
26.67%
SMA100
75.25%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
16.88-31.99
52W High
+30.9%
52W Low
+153.63%
RSI
59.26
Rel Volume
3.14
Avg Volume
4.55K
Volume
14.28K
Perf Week
2.71%
Perf Month
8.68%
Perf Quarter
81.16%
Perf Half Y
87.87%
-
-
-
-
Beta
0.93
-
-
Volatility
0.78%, 1.02%
Prev Close
0.55%
Price
40.58
Change
-2.48%

BBC Financial Performance

BBC Dividend History

BBC Frequently Asked Questions

What is Virtus LifeSci Biotech Clinical Trials ETF stock symbol ?

Virtus LifeSci Biotech Clinical Trials ETF is a US stock and trading under the symbol BBC

What is Virtus LifeSci Biotech Clinical Trials ETF stock quote today ?

Virtus LifeSci Biotech Clinical Trials ETF stock price is $40.58 today.

Is Virtus LifeSci Biotech Clinical Trials ETF stock public?

Yes, Virtus LifeSci Biotech Clinical Trials ETF is a publicly traded company.

Something similar

Top by Market Cap
GOOG
MIX.JO
M&M.NS
ABEA.DE
V
Top Correlated ETFs
WDNA
DWAS
Top Correlated Stocks
NUVL
VRDN
CCOI
2611.TW
1304.TW
Similar Market Cap
PHGE
GVC.TO
FRSX
SIDU
ACER

Company Profile

Financial Services Asset Management
  • Volume Average 4.55K
  • Market Capitalization 11.64M
  • Headquarters US
  • IPO Date 2014-12-17

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.